Clinical Trial Update: A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection [Phase 3]

View source ↗

Summary

Phase III trial update for Recombinant Human Apo-2 Ligand for Injection in stage IV non-small cell lung cancer; the current trial status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Recombinant Human Apo-2 Ligand for Injection

Snippet

Sponsor: Shanghai Gebaide Biotechnology Co., Ltd. | Conditions: Non-small-cell Lung Cancer (NSCLC) Stage IV | Phase 3 | Status: UNKNOWN